Transparency data

The 2019 voluntary scheme for branded medicines pricing and access operational review: 13 February 2023

Minutes of a meeting held between government, NHS England and the ABPI to review the operation of the 2019 voluntary scheme for branded medicines pricing and access.

From:
Department of Health and Social Care
Published
30 June 2023

Documents

13 February 2023 minutes

HTML

Details

The voluntary scheme for branded medicines pricing and access (VPAS) is a non-contractual voluntary agreement between the government, (constituted of the Department of Health and Social Care (DHSC), NHS England and the governments of Scotland, Wales and Northern Ireland) and the Association of the British Pharmaceutical Industry (ABPI), the representative body of the UK pharmaceutical industry.

VPAS aims to:

  • improve patient access to medicines by getting the best value and most effective medicines into use more quickly
  • keep the branded medicine bill affordable for the NHS through a cap in growth of branded sales
  • support innovation and a successful life sciences industry in the UK

Operational review meetings are held every 6 months.

Updates to this page

Published 30 June 2023

Sign up for emails or print this page

Related content